Free Trial

Merus (MRUS) Competitors

Merus logo
$41.60 -1.61 (-3.73%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$47.25 +5.65 (+13.58%)
As of 05/22/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MRUS vs. VTRS, MRNA, ASND, QGEN, ROIV, RVMD, ELAN, BPMC, BBIO, and VRNA

Should you be buying Merus stock or one of its competitors? The main competitors of Merus include Viatris (VTRS), Moderna (MRNA), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry.

Merus vs.

Merus (NASDAQ:MRUS) and Viatris (NASDAQ:VTRS) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking.

96.1% of Merus shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 4.6% of Merus shares are held by company insiders. Comparatively, 0.1% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Viatris had 15 more articles in the media than Merus. MarketBeat recorded 32 mentions for Viatris and 17 mentions for Merus. Merus' average media sentiment score of 1.13 beat Viatris' score of -0.02 indicating that Merus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merus
11 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Viatris
0 Very Positive mention(s)
2 Positive mention(s)
26 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral

Viatris has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merus$54.73M52.61-$154.94M-$4.08-10.20
Viatris$14.33B0.70$54.70M-$3.17-2.68

Merus received 343 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 67.90% of users gave Merus an outperform vote while only 34.85% of users gave Viatris an outperform vote.

CompanyUnderperformOutperform
MerusOutperform Votes
366
67.90%
Underperform Votes
173
32.10%
ViatrisOutperform Votes
23
34.85%
Underperform Votes
43
65.15%

Viatris has a net margin of -5.87% compared to Merus' net margin of -680.61%. Viatris' return on equity of 16.46% beat Merus' return on equity.

Company Net Margins Return on Equity Return on Assets
Merus-680.61% -38.89% -31.16%
Viatris -5.87%16.46%7.09%

Merus has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.

Merus currently has a consensus price target of $84.54, indicating a potential upside of 103.22%. Viatris has a consensus price target of $10.50, indicating a potential upside of 23.53%. Given Merus' stronger consensus rating and higher possible upside, analysts clearly believe Merus is more favorable than Viatris.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merus
0 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
2 Strong Buy rating(s)
3.13
Viatris
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75

Summary

Merus beats Viatris on 12 of the 19 factors compared between the two stocks.

Get Merus News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRUS vs. The Competition

MetricMerusPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.88B$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-10.539.0626.7119.71
Price / Sales52.61251.51386.08120.53
Price / CashN/A65.8538.2534.62
Price / Book6.746.456.774.50
Net Income-$154.94M$143.98M$3.23B$248.22M
7 Day Performance0.10%0.38%0.48%-0.78%
1 Month Performance-0.55%2.14%9.10%11.53%
1 Year Performance-5.60%-0.33%18.56%8.99%

Merus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRUS
Merus
3.2298 of 5 stars
$41.60
-3.7%
$84.54
+103.2%
-4.1%$2.88B$54.73M-10.5337News Coverage
Positive News
Analyst Forecast
Options Volume
High Trading Volume
VTRS
Viatris
1.8962 of 5 stars
$8.76
-0.9%
$10.50
+19.9%
-21.8%$10.28B$14.33B-11.8437,000Trending News
MRNA
Moderna
4.4407 of 5 stars
$26.39
+6.2%
$53.95
+104.4%
-83.6%$10.21B$3.14B-2.843,900Trending News
Analyst Forecast
Gap Up
High Trading Volume
ASND
Ascendis Pharma A/S
3.3776 of 5 stars
$160.33
+1.7%
$216.07
+34.8%
+22.0%$9.78B$368.70M-22.58640
QGEN
Qiagen
3.9804 of 5 stars
$42.77
+0.3%
$48.42
+13.2%
+0.1%$9.51B$2.00B119.096,030Positive News
ROIV
Roivant Sciences
2.1187 of 5 stars
$10.84
+0.5%
$17.50
+61.4%
-3.1%$7.73B$122.59M-72.26860Positive News
Upcoming Earnings
Insider Trade
RVMD
Revolution Medicines
4.3594 of 5 stars
$39.93
+1.0%
$67.08
+68.0%
-2.4%$7.44B$742,000.00-11.12250Positive News
ELAN
Elanco Animal Health
3.2246 of 5 stars
$13.24
+2.5%
$15.17
+14.6%
-25.1%$6.58B$4.43B33.109,800Gap Up
BPMC
Blueprint Medicines
2.6082 of 5 stars
$101.21
-0.5%
$126.56
+25.0%
-2.3%$6.54B$562.12M-93.71640Positive News
Insider Trade
BBIO
BridgeBio Pharma
4.5993 of 5 stars
$33.69
-0.4%
$57.09
+69.5%
+12.6%$6.40B$127.42M-11.82400Insider Trade
VRNA
Verona Pharma
2.6573 of 5 stars
$72.58
+1.8%
$81.50
+12.3%
+476.9%$5.88B$118.54M-37.8030Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:MRUS) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners